Morgans names 2 more of the best ASX shares to buy in December

The team at Morgans has been busy picking out its best ASX share ideas for December.

These are the shares that its analysts think offer the highest risk-adjusted returns over a 12-month timeframe and are supported by a higher-than-average level of confidence.

The first two shares we looked at can be found here. Read on for the next two:

ResMed Inc (ASX: RMD)

This sleep treatment focused medical device company has been named as one of Morgans’ best ideas.

Morgans likes ResMed largely due to its strong position in digital health. It is expecting the company’s portfolio of cloud-connected products to be a key driver of growth in the future. The broker explained:

While we expect the next few quarters to be volatile as COVID-related demand for ventilators continues to slow and core sleep apnoea volumes gradually lift, nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.

Morgans currently has an add rating and $37.00 price target on ResMed’s shares.

Westpac Banking Corp (ASX: WBC)

If you’re looking for banking sector exposure then Morgans thinks that Westpac could be the way to do it.

The broker believes that Australia’s oldest bank is well-placed to deliver the strongest return on equity improvement thanks partly to its major cost cutting plans. Its analysts expect this to support attractive dividend yields. It commented:

We view WBC as having the greatest potential for return on equity improvement amongst the major banks if its business transformation initiatives prove successful. The sources of this improvement include improved loan origination and processing capability, cost reductions (including from divestments and cost-out), rapid leverage to higher rates environment, and reduced regulatory credit risk intensity of non-home loan book. Yield including franking is attractive for income-oriented investors, while the ROE improvement should deliver share price growth.

Morgans has an add rating and $25.80 price target on the bank’s shares.

The post Morgans names 2 more of the best ASX shares to buy in December appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 5 things to watch on the ASX 200 on Tuesday
• Will the RBA raise rates again next week? Here’s what Westpac expects
• Buy Westpac and this ASX dividend share: broker
• Why did the Westpac share price lag the ASX 200 in November?
• The 3 best-performing ASX 200 bank shares in November revealed

Motley Fool contributor James Mickleboro has positions in Westpac Banking. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Westpac Banking. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/3YAvWB9